Brief: Kiromic Biopharma Inc Says Cash And Cash Equivalents Were $36,161,800 As Of September 30, 2021
11/03/2022 21:03
March 11 (Reuters) - Kiromic Biopharma Inc KRBP.O :
* KIROMIC BIOPHARMA PROVIDES BUSINESS UPDATE AND REPORTS
THIRD
QUARTER 2021 FINANCIAL RESULTS
* KIROMIC BIOPHARMA INC - CASH AND CASH EQUIVALENTS WERE
$36,161,800 AS OF SEPTEMBER 30, 2021, COMPARED TO $10,150,500 AS
OF DECEMBER 31, 2020
Source text for Eikon: ID:nBw3nwCZPa
Further company coverage: KRBP.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Kiromic Biopharma
See all newsBrief: Kiromic Biopharma Files For Offering Up To 1 Million Units
Brief: Kiromic Biopharma Applies To List Common Stock On The NYSE American Under Symbol 'KRBP'
Brief: Kiromic Biopharma Advances Deltacel-01 Into Expansion Phase Following Safety Monitoring Committee's Unanimous Recommendation
Brief: Kiromic Biopharma Reports Favorable Results At Six Weeks From Fourth Patient In Deltacel-01 Clinical Trial
Brief: Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site